Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis

ConclusionIn pediatric patients, rituximab was well tolerated and effective with an overall safety profile comparable with that of rituximab-treated adult patients with GPA or MPA. Rituximab was associated with a positive benefit-risk profile for use in pediatric patients with active GPA or MPA.

Source: Arthritis and Rheumatology - June 24, 2021 Category: Rheumatology Authors: Paul Brogan, Rae S. M. Yeung, Gavin Cleary, Satyapal Rangaraj, Ozgur Kasapcopur, Aimee O. Hersh, Suzanne Li, Dusan Paripovic, Kenneth Schikler, Andrew Zeft, Claudia Bracaglia, Despina Eleftheriou, Pooneh Pordeli, Simone Melega, Candice Jamoi Tags: FULL LENGTH Source Type: research